Glaucoma News and Research

Latest Glaucoma News and Research

Telephone intervention improves medication adherence in patients with glaucoma

A telephone intervention trial was associated with improvement in glaucoma medication adherence in both the treatment group and the control group but, when the two groups were compared, interactive telephone calls and tailored print materials did not significantly improve adherence, according to a report of a randomized controlled clinical trial published Online First by Archives of Ophthalmology, a JAMA Network publication.

13 Jun 2012

Lexicon presents six posters on LX4211 at ADA meeting

Lexicon Pharmaceuticals, Inc. will present six posters summarizing the mechanism of action and safety of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) currently in mid-stage development for type 2 diabetes, at the 72nd Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, Pennsylvania during the Saturday morning poster session on June 9, 2012.

10 Jun 2012

Ocular pulse amplitude reliable, safe screening test for carotid artery stenosis

A simple eye test may someday offer an effective way to identify patients who are at high risk for stroke, say researchers at the University of Zurich. They showed that a test called ocular pulse amplitude (OPA) can reliably detect carotid artery stenosis (CAS), a condition that clogs or blocks the arteries that feed the front part of the brain.

8 Jun 2012

Pituitary tumors may lead to glaucomatous changes

Certain tumors of the pituitary gland are associated with glaucomatous abnormalities of the optic nerve head, such as enlarged beta zone, an international research team reports.

30 May 2012

Brain cells prune circuits in the brain by eating away excess synapses

We’re born with our brains prewired, but as information comes in from our environment, this circuitry is updated. A study from Boston Children’s Hospital provides a new glimpse of how this happens: Brain cells known as microglia, tuned into the crosstalk between neurons, literally engulf unnecessary connections, known as synapses, and prune them away.

24 May 2012

ACADIA first quarter net loss increases to $6.2 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2012.

9 May 2012

Amakem presents key preclinical data on AMA0076 at ARVO meeting

Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.

8 May 2012

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting.

8 May 2012

Ocular Therapeutix initiates travoprost-loaded punctum plug trial in glaucoma

Ocular Therapeutix, Inc. announced today the commencement of a sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma.

5 May 2012

Lexicon to receive funding for LX4211 Phase 2 trial in type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that an independent, non-profit organization will provide funding to support the Phase 2 development of LX4211 in type 1 diabetes.

4 May 2012

Lexicon first quarter revenues decrease 50% to $0.3 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2012.

3 May 2012

IRIDEX launches non-invasive MicroPulse Laser Trabeculoplasty for glaucoma

IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse technology. The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).

27 Apr 2012

Checklist for seniors to reduce risk of falls

For those 65 and older, falling can be fatal; in fact, the Centers for Disease Control and Prevention (CDC) reports that falls are the leading cause of injury-related deaths among this age group, and some 40 percent of seniors fall at least once each year. Additionally, one in four who sustains a hip fracture from a fall will die within a year, and another 50 percent will never return to their pre-fall level of mobility.

27 Apr 2012

Caffeine increases eye's ability to produce tears

Researchers at the University of Tokyo's School of Medicine have shown for the first time that caffeine intake can significantly increase the eye's ability to produce tears, a finding that could improve treatment of dry eye syndrome. This common eye condition affects about four million people age 50 and older in the United States.

18 Apr 2012

Viewpoints: Santorum pushed Romney on health care; GOP's 'classic male mistake'; ACOs and the anti-trust challenge

The Pennsylvanian was also by far the most effective Republican critic of RomneyCare. When he stood on stage in a debate and took apart the Massachusetts health law as a prototype for ObamaCare, Mr. Romney realized he couldn't coast to the nomination. That's when the former Massachusetts Governor came out with his own tax cut and tax reform plan to appeal to economic conservatives.

12 Apr 2012

MacuCLEAR to initiate MC-1101 Phase III studies on early-stage AMD

MacuCLEAR, Inc., a clinical stage specialty pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today it is beginning Phase III studies for its lead compound, MC-1101, for early-stage (Dry) age-related macular degeneration (AMD), based on positive feedback during the company's end-of-Phase II meeting with the FDA.

12 Apr 2012

OphthaliX completes CF101 preclinical studies on Anterior Uveitis

OphthaliX announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis

10 Apr 2012

Key finding in regulation of intraocular pressure in glaucoma

A six-year collaboration between two faculty members of Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has yielded new insight regarding the regulation of intraocular pressure (IOP) in glaucoma - an irreversible blinding disease that causes progressive visual impairment due to optic nerve damage and is the leading cause of blindness worldwide.

6 Apr 2012

Stress-induced tolerance can prevent glaucoma

Working in mice, scientists at Washington University School of Medicine in St. Louis have devised a treatment that prevents the optic nerve injury that occurs in glaucoma, a neurodegenerative disease that is a leading cause of blindness.

4 Apr 2012

FDA approves Teva's QNASL nasal aerosol corticosteroid

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

26 Mar 2012